Opthea Limited (OPT.AX)
| Previous close | 0.3350 |
| Open | 0.3350 |
| Bid | 0.3200 x 1566800 |
| Ask | 0.3400 x 380500 |
| Day's range | 0.3150 - 0.3400 |
| 52-week range | 0.3150 - 1.1950 |
| Volume | |
| Avg. volume | 531,284 |
| Market cap | 158.583M |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Oct 2004 |
| 1y target est | N/A |
- GlobeNewswire
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company’s Chief Financial Officer will present at H.C. Wainwright’s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023. Mr. Morris will present on Wed
- GlobeNewswire
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of strong demand from both existing and new domestic and offshore institutional investors Opthea has accepted an additional A$10.0 million in oversubscriptions, increasing the placement size to A$20.0 million and the total size of the capital raising to A$90.0 millionThe Placement and Institutional Entitlement Offer raised approximately A$73.7mThe ful
- GlobeNewswire
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the American Medical Association’s United States Adopted Names (USAN) Council, in consultation with the World Health Organization’s International Nonproprietary Names (INN) Expert Committee, has approved and adopted the nonproprietary drug name “soziniber
